In The News Posted February 19, 2022 Share Posted February 19, 2022 TIANJIN, China, Feb. 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™) has been approved by the Joint Prevention and...View the full article Quote Link to comment Share on other sites More sharing options...
Recommended Posts